Genmab A/S (GMAB) Stock Analysis
Temp Headwind edge
Healthcare · Biotechnology
Sell if holding. Momentum 3.8/10 is below the 5.0 floor at $25.68 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Consecutive earnings misses (2).
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma... Read more
Sell if holding. Momentum 3.8/10 is below the 5.0 floor at $25.68 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Consecutive earnings misses (2). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 6.0/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent Developments — Genmab A/S
Latest news
- Genmab Q1 2026 earnings preview - MSN — MSN neutral
- What To Expect From Genmab AS (GMAB) Q1 2026 Earnings - GuruFocus — GuruFocus neutral
- GMAB Earnings Preview: Genmab Q1 2026 on May 7 - Meyka — Meyka neutral
- Why Genmab Stock Popped on Friday - MSN — MSN positive
- Genmab A (GMAB) price target decreased by 61.97% to 34.46 - MSN — MSN negative
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.8/10 is below the 5.0 floor at $25.68 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Consecutive earnings misses (2). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $24.58. Score 6.0/10, moderate confidence.
Take-profit target: $32.66 (+27.2% upside). Prior stop was $24.58. Stop-loss: $24.58.
Consecutive earnings misses (2); Negative momentum.
Genmab A/S trades at a P/E of 20.0 (forward 14.4). TrendMatrix value score: 7.5/10. Verdict: Sell.
27 analysts cover GMAB with a consensus score of 3.8/5. Average price target: $38.
What does Genmab A/S do?Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of...
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.